Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for June 2012
June 1, 2012
- Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO data Presented at the European Atherosclerosis Society 2012 Meeting
- BNC105 Trial Data Presented at American Society for Clinical Oncology (ASCO)
- Halozyme Therapeutics to Present New Data on the Company's Ultrafast Insulin Programs at ADA 2012
- UCB to showcase broad immunology portfolio at EULAR 2012
- Diabetes Drug Linked to Increased Risk of Bladder Cancer
- Onconova Presents Clinical Trial Data for Oral Rigosertib at ASCO Annual Meeting
- Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for Aubagio (teriflunomide) in Relapsing Multiple Sclerosis
- Patients Often Have Elevated LDL Particle Levels Despite Normal Levels of Lipoprotein(a)
- Researchers Present Findings on Chronic Myeloid Leukemia Treatment Patterns and Responses Involving Imatinib
- immatics presents encouraging overall survival data from a phase 2 study in Advanced Colorectal Cancer at the ASCO Annual Meeting
- OMACETAXINE MEPESUCCINATE SHOWS ACTIVITY IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE BECOME RESISTANT TO OR INTOLERANT OF PRIOR TYROSINE KINASE INHIBITORS (TKIs) (1,2,3)
- Data From an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts
- Cyclacel Presents New Phase 2 Data of Sapacitabine for MDS at ASCO Annual Meeting
June 4, 2012
- New Phase II data on investigational drug NGR-hTNF presented at ASCO
- Galena Biopharma Presents NeuVax Phase 1/2 Boosters Improve Disease-Free Survival at 60-Month Median Follow-Up
- Updated analysis of phase III ALSYMPCA study for Algeta?s investigational compound radium-223 dichloride to be presented at the 48th annual ASCO meeting
- Two New Analyses Reinforce Consistent Efficacy of Novartis Therapy Gilenya Across Wide Range of Relapsing MS Patients
- Roche data showed that people with metastatic colorectal cancer lived longer when they continued on Avastin plus chemotherapy
- Afatinib, Boehringer Ingelheim's investigational compound, demonstrates progression free survival of almost one year in patients with EGFR mutation positive, advanced non-small cell lung cancer in pivotal phase III trial
- Phase III Data on Bayer's Regorafenib Met Primary Endpoint Showing Significant Improvement in Progression-Free Survival in Patients with GIST
- Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial
- Genentech's Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer Worsening or Death by 35 Percent in Pivotal Phase III Trial
- Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus Chemotherapy
- CytRx to Hold Conference Call Today at 10:00 a.m. Eastern Time to Discuss Favorable Results from INNO-206 Clinical Trial in Soft Tissue Sarcoma
- Synta Announces Ganetespib Presentations at the Annual Meeting of the American Society for Clinical Oncology
- Clinical Data Presented on Orteronel (TAK-700) without Steroids in Non-Metastatic Prostate Cancer
- Oramed Pharmaceuticals to Present at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia, PA, June 8-12, 2012
- Large U.S. Multi-Center Study Confirms Safety and Efficacy of SIR-Spheres microspheres in More Than 600 Patients with Unresectable Liver Metastases
- Active Biotech's and Ipsen's Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer
- Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer
- Zytiga Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
- Islet Sciences Announces Participation at the 2012 American Transplant Congress
- Alnylam Presents Data from its Phase I Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting
- Purdue Pharma L.P. to Present Data on Physician Understanding of the Risk Evaluation and Mitigation Strategy (REMS) for Butrans (buprenorphine) Transdermal System CIII Data at International Society of Pharmacoeconomics and Outcomes Research Annual Meeting
- Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer
- CER Study Finds No Observable Difference Between Generic and Branded Statins in Preventing Cardiovascular Events
- Cabozantinib Meets Primary Endpoint of Progression Free Survival in Phase 3 Pivotal Trial in Medullary Thyroid Cancer
- FibroGen Announces Preliminary Clinical Findings on the Positive Effects of FG-4592, Its Investigational HIF-PHI Therapy for Anemia, on Lowering Blood Pressure and Cholesterol in Patients With Chronic Kidney Disease
- Pharmacyclics Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at American Society of Clinical Oncology (ASCO) Annual Meeting
- MiniVax's Pneumocystis Vaccine Candidate Induces Significant anti-Pneumocystis Antibody Responses and Reduced Fungal Load
- New Data for Jakafi (ruxolitinib) Presented at 2012 ASCO Annual Meeting
- Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of the BENEFIT and BENEFIT-EXT Clinical Trials of NULOJIX (belatacept)
- Caris Target Now ASCO Presentations Underscore Importance of Molecular Profiling in Pancreatic Cancer and Uveal Melanoma
- NewLink Genetics HyperAcute Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients With Non-Small Cell Lung Cancer
- Immunomedics Reports Final Survival Data From Two-Part Pancreatic Cancer Study With Yttrium-90-Labeled Clivatuzumab Tetraxetan Combined With Gemcitabine
- Cyclacel Presents Phase 1 Data of Sequential Sapacitabine and Seliciclib in Advanced Solid Tumors at ASCO Annual Meeting
- Data From Phase 1 and Phase 1B Studies of NewLink Genetics' IDO Pathway Inhibitor (NLG8189) Presented at 2012 ASCO Annual Meeting
- Esperance Pharmaceuticals Presents Results From Phase 1 Study of EP-100 in Advanced, Refractory LHRH-Receptor Expressing Solid Tumors at ASCO
- Antisense Pharma Presents Trabedersen Phase I/II Complete Data at ASCO
- NewLink Genetics Reports Two- and Three-Year Overall Survival Data From Its Phase-2 HyperAcute(R) Pancreas (algenpantucel-L) Immunotherapy Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting
- New Data on PMX-30063 Presented at ASCO Suggest Strong Potential as Treatment for Oral Mucositis
- Cleveland BioLabs Reports Strong Survival Results Which Met the Primary Endpoint of Its GLP Efficacy Study With Radiation Countermeasure CBLB502
- Phase III Study: Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy
- Immunovaccine?s DPX-0907 Demonstrates Ability to Generate Promising Immune Reponses in Multiple Cancers in a Clinical Trial Presented at ASCO Annual Meeting
- Xcovery Presents Phase 1 Clinical Results at Asco Annual Meeting
- Tekmira's LNP Technology Enables ALN-VSP Clinical Data
- Meta-analysis of Navidea Biopharmaceuticals Lymphoseek Phase 3 Data Compared to Standard of Care Techniques Published in Conjunction with the ASCO Annual Meeting
- Marshall Edwards Presents Results From Clinical Trial Of Lead Oncology Drug Candidate ME-143
- Active Biotech?s and Ipsen?s Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer
- ImmunoGen, Inc. Announces Presentation of New Clinical Data for SAR3419
- Incyte Presents Results from a Phase I Trial of INCB024360, a Novel Oral Inhibitor of Indoleamine Dioxygenase-1 (IDO1), at ASCO
- ARIAD Announces Updated Data from Pivotal PACE Trial of Ponatinib, Its Investigational pan-BCR-ABL Inhibitor
- MEK162 Shows Promising Clinical Activity in Ongoing Phase 2 Trial
- Promising Data for KRAS Mutant Advanced NSCLC Patients Presented at ASCO
- ChemoFx® Provides Tumor-Specific Information That May Assist in Personalized Chemotherapy Selection
- PerkinElmer to Host Personalized Global Health Summit Webcast
- BTG announces data presentation on Voraxaze (glucarpidase) at the American Society of Clinical Oncology Annual Meeting
- Vanda Pharmaceuticals to Present at SLEEP 2012 26th Annual Meeting of the Associated Professional Sleep Societies
- Jennerex Presents JX-594 Clinical Data at 2012 American Society of Clinical Oncology Annual Meeting
- Adamas Pharmaceuticals Presents Update On Nurelin Program At Cambridge Healthtech Institute's Parkinson's Conference
- Aeterna Zentaris: Phase 3 Data for Perifosine in Colorectal Cancer Presented at ASCO Meeting
- BioSpecifics Technologies Corp. Announces Positive Top-Line Phase III Data from XIAFLEX Clinical Trials for Treatment of Peyronie's Disease
- Afatinib demonstrates significant progression-free survival of almost one year in EGFR mutation-positive advanced NSCLC
- Auxilium Pharmaceuticals, Inc. Announces Positive Top-line Results from Both Phase III Trials of XIAFLEX for the Potential Treatment of Peyronie's Disease
- Updated Analysis of Phase III ALSYMPCA Study for Bayer's Investigational Compound Radium-223 Dichloride to be Presented at the 48th Annual ASCO Meeting
June 5, 2012
- Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN and Belinostat at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
- Galena Biopharma Announces NeuVax (E75) Improves Disease-Free Survival at 60-Month Median Follow-Up
- PHT Corporation Founder Dr. Stephen Raymond and Europe GM Valdo Arnera, MD Address the Impact of eClinical Technology Innovation on Biopharmaceuticals, CROs and Patients at DIA 2012
- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company to Feature 30 Presentations on Type 1 and Type 2 Diabetes at the 72nd American Diabetes Association Scientific Sessions
- Boston Biotech Industry Takes Center Stage at the 2012 BIO International Convention
- Celator Pharmaceuticals Announces Presentations of Positive Survival Analyses from CPX-351 Studies at ASCO Annual Meeting
- Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue in Advanced Prostate Cancer
- Royer Biomedical, Inc. receives FDA approval to proceed with Human Testing (IND 111446) on 5/25/2012 for its AppliGel Polymer Drug Delivery System
- Janssen Research & Development to Present Results from Five Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes
- Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes
- Generex Announces Presentation of New Immune Response Data from AE37 Phase II Breast Cancer Trial at ASCO 2012
June 6, 2012
- Silence Therapeutics Announces Safe and Effective Dose Successfully Identified in Phase I Study of Atu027 and Potential Fund Raising
- Roche?s Roactemra Improved Rheumatoid Arthritis Signs and Symptoms Significantly More Than Adalimumab As Single-Agent Therapy
- Hyperion Therapeutics' Glycerol Phenylbutyrate Meets Primary Endpoint in Phase II Study in Episodic Hepatic Encephalopathy
- Orencia (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
- New Analysis of Phase III Trials Shows Gout Patients with Chronic Kidney Disease at Any Stage Responded to KRYSTEXXA Presented in Oral Session at EULAR 2012
- Generex Announces ASCO 2012 Podium Presentation Showcasing Antigen Express AE37 Cancer Vaccine Technology
- Novartis Phase III study showed 62% of patients with most severe form of childhood arthritis were symptom-free with ACZ885 treatment
- Role of Mobile in Multi-Media Disease Intervention Programs Presented by dLife Healthcare Solutions at Mobile Health Plugin Conference, June 11
- Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
- BioCryst Presents Results from Its BCX4208 Gout Program at the Annual European Congress of Rheumatology
- RAPID-PsA study showed that certolizumab pegol improved the signs and symptoms of psoriatic arthritis
- Hundreds of Participants Kick Off 2nd International Summit on the Future of Health Privacy
- OXiGENE Announces Publication of Key Data Showing Antitumor Activity of ZYBRESTAT Combined With Bevacizumab
June 7, 2012
- r-FSH biosimilar meets primary endpoint in phase III pivotal study
- Curis Announces Publication of Erivedge Data in the New England Journal of Medicine
- SFL?s Managing Director to Speak at Life Science Network Basel Event
- Sudler eHealth Group Announces Second HEALTH + TECHNOLOGY SUMMIT
- Japan Pharma Portfolio Finds Renewed Strength through Record Growth in 2012
- Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting
- Galectin Therapeutics to Host Symposium on Galectin Science and Therapeutic Applications September 17-19, 2012
- Genocea Announces New Research Identifying Potential Vaccine Candidates for Chlamydia
- Newly Identified Protein Function Protects Cells During Injury
- Preclinical Research with Proteonomix's UMK-121 Featured in Oral Presentation at the International Society for Cellular Therapy 18th Annual Meeting
- Data From Follow-Up Study of KALYDECO (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People with Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D)
- NCI Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID® Cancer Vaccine Following Rituximab-Chemotherapy in Mantle Cell Lymphoma Study
- Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients With Lupus at 2012 EULAR Congress
June 8, 2012
- Amgen Announces Top-Line Results Of Phase 3 Sensipar/Mimpara EVOLVE Trial
- Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
- Post Hoc Analysis Indicated That Timing And Magnitude Of Initial Response To Certolizumab Pegol Predicted Likelihood Of Low Disease Activity At Week 28 In Patients With Active Moderate To Severe Rheumatoid Arthritis
- Lundbeck Encourages Epilepsy Community to Attend Upcoming Partners Against Mortality in Epilepsy (PAME) Conference
- The New England Journal of Medicine Publishes Efficacy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis
- Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
- Assessment Of Abuse-Deterrent And Tamper-Resistant Technologies: From The Bench-Top To The Users
- EuroMedtech 2012 in Grenoble Spurs Collaborations Among a Diversity of Medtech Players
- Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
- NTT DATA Licenses DATATRAK ONE for China
June 11, 2012
- KYTHERA Biopharmaceuticals Announces Presentation of Positive Results from Second ATX-101 European Phase III Trial for Reduction of Submental Fat
- ASCO Highlight: New Trial Results Show Lung Cancer Drug Delays Cancer Progression Compared to Standard Chemotherapy
- Epratuzumab Results in Lupus Presented at 2012 Annual European Congress of Rheumatology
- Investigational Ultra Long-Acting Insulin Degludec Reduced Rates of Nocturnal Hypoglycemia in Type 2 Diabetes Patients Versus Insulin Glargine
- ChemoCentryx Announces Peer-Reviewed Publication of Positive Phase 2 Clinical Data with CCX354, a Novel Inhibitor of Chemokine Receptor CCR1 in Patients with Rheumatoid Arthritis
- Novartis Data at ADA Demonstrate Galvus Efficacy and Safety in Combination With Insulin; VERIFY Study on Potential Early Use of Vildagliptin Launches
- Novartis Drug Gilenya Shows Long-Term Efficacy and Safety According to New Data From Extension of Phase III Head-to-Head Study
- Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association's 72nd Scientific Sessions
- New Data Show Investigational Compound Dapagliflozin Demonstrated Significant Reductions in Blood Sugar Levels When Added to Sitagliptin in Adults with Type 2 Diabetes at 24 Weeks, with Results Maintained Over 48 Weeks
- Lantus Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes
- BYETTA Provided Greater Glycemic Durability and Overall Glycemic Control than Amary® in Patients with Type 2 Diabetes
- BYDUREON Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes
- BYDUREON Was Associated with Significant and Sustained Glycemic Control at Four Years
- Seventy Percent of Totally Blind Individuals With Sleep Complaints Suffer From Chronic Circadian Rhythm Sleep Disorder
- FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes
- Grifols Publishes Positive Phase I Safety Results for Plasmin, a Novel, Direct-Acting Thrombolytic, in the Journal of Thrombosis and Haemostasis
- Women Health Expert GC-Rise Sponsors Nationwide Anti-Cancer Campaign
- Sanofi Announces Results of ORIGIN, the World's Longest and Largest Randomized Clinical Trial in Pre- and Early Diabetes
- A New Study With 'Real World' Data Shows Greater Efficacy of Victoza, With Weight Loss and Cost-Effectiveness, in Type 2 Diabetes Compared to Twice-Daily Exenatide and DPP-4 Inhibitors (11 June 2012)
- ISPE and FDA Discuss Quality Standards at Joint CGMP Conference
- Canagliflozin Provided Substantial and Sustained Glycemic Improvements as Monotherapy and in Add-On Combinations in Adults with Type 2 Diabetes in Five Phase 3 Studies
- Positive Results from First Human Clinical Trials of a First-Generation Artificial Pancreas System is Significant Step Forward for Millions with Type 1 Diabetes
- Data Comparing Navidea's AZD4694 to Gold-Standard 11C-PIB in Beta Amyloid Imaging Presented at Society of Nuclear Medicine Meeting
- LILLY (ELI) & COMPANY - 90-week data suggest sustained glucose reduction and weight loss with investigational SGLT-2 inhibitor, empagliflozin
- Lyonbiopôle: BE AHEAD with the 6th Annual Fast -Track R&D Partnering with France (FTRD) on June, 18th 2012
- assisTek Unveils eDiary for Collection of Patient-Reported Adverse Events
- Medidata Solutions to Lead Discussions on Cloud-based Clinical Technology at 48th DIA Annual Meeting
- Cara Therapeutics Reports Positive Results from Phase II Trial of Novel Peripheral Kappa Agonist, CR845, in Acute Post-Operative Pain
- New Epidemiological Data Provide Additional Safety Evidence for Lantus
- Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
- "AWAKEN" Survey Finds Only 50 Percent of Americans Understand Significant Health Impact of Narcolepsy, and Many Physicians Not Comfortable Diagnosing the Sleep Disorder
June 12, 2012
- Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
- Alnylam and Collaborators Publish New Pre-clinical Results with an RNAi Therapeutic Approach for Inducing Endogenous Erythropoiesis for the Treatment of Anemia
- Global survey finds one in four type 2 diabetes patients do not take basal insulin as prescribed and more than a third suffer from hypoglycemia
- GREER Reports Positive Findings from Large Phase III Clinical Trial Evaluating Sublingual Immunotherapy for Ragweed Allergies
- Thiazolidinedione Treatment in Patients with Type 2 Diabetes Appears to be Associated with Increased Risk for Diabetic Macular Edema
- Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
- HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
- Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
- PsychoGenics Inc. Announces Positive Efficacy Data in Levodopa Induced Dyskinesia in Parkinson's Patients
- Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
June 13, 2012
- Greer Reports Positive Findings From Large Phase III Clinical Trial Evaluating Sublingual Immunotherapy for Ragweed Allergies
- New Phase III Data Showed Merck?s Investigational Insomnia Medicine Suvorexant Improved Patients' Ability to Fall Asleep and Stay Asleep
- Cannabis Science Published on HIV Haven.com ?Cannabinoid Research Shows Promise for HIV TAT Inhibition? Authored by Dr. Robert Melamede, Ph.D. and Dr. David Miller, Ph.D.
- GTx Announces Poster Presentation on the Prevalence and Impact of Hypogonadism in Cancer Patients with Muscle Wasting from its Phase IIb Enobosarm Clinical Trial at the Endocrine Society's 2012 Annual Meeting
- Teva Announces AZILECT (Rasagiline Tablets) Data to Be Presented at the 16th Annual International Congress of Parkinson's Disease and Movement Disorders
- Fuse Science Sets New Standard of Transdermal Delivery with Groundbreaking Scientific Results
- Oncolytics Biotech Inc. Announces Publication of Translational Clinical Trial Results in Science Translational Medicine
- Immunomedics Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma
- Immunomedics Reports Updated Results From Phase I Pretargeting Therapy Study in Colorectal Cancer
- Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study
- Masitinib Treatment of Progressive Multiple Sclerosis Publication in BMC Neurology
- Azaya Therapeutics Reports Results of Phase I Clinical Trial
- Aeterna Zentaris: Poster on Phase 1 Results for Perifosine in Neuroblastoma to be Presented at Upcoming Neuroblastoma Research Conference in Toronto
- As Pertussis Cases Climb, Survey Shows Most Parents With Young Children Overlook Vital Precaution That Helps Protect Babies
- Ophthotech's Novel Anti-PDGF Combination Agent Fovista Demonstrated Superior Efficacy over Lucentis Monotherapy in Large Controlled Wet AMD Trial
June 14, 2012
- Innovative Grass Pollen Allergy Vaccine Shows Efficacy in Phase Iia Trial
- Interim data from clinical trial of ReNeuron?s stem cell therapy for stroke to be presented at leading scientific conference
- Teva Announces Top-Line Results from GALA Phase III Trial Evaluating a New Dosage for Glatiramer Acetate Given Three Times Weekly for Relapsing-Remitting Multiple Sclerosis
- CytoPharm and Amarillo Biosciences Announce Positive HCV Study Results: Oral Interferon Found to Reverse Thrombocytopenia; Reduced Relapse Rate Seen in Patients with Mild Fibrosis
- Dyax Reports Results of Interim Analysis of Phase 2 Trial of Ecallantide for Acute Treatment of ACE Inhibitor-Induced Angioedema
- Generex Announces Publication of Abstract at ASCO 2012 Showing Potential of Antigen Express AE37 Immunotherapeutic Cancer Vaccine Technology in Prostate Cancer
- Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming ENDO Meeting
- ASCO Spotlight: Antibody-Drug Conjugates Are Here!
June 15, 2012
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO
- MedVantx MedStart Solves Problem Highlighted in Study Published in Journal of the American Board of Family Medicine - Expired Medications in Physician Office Sample Closets
- Eczema in Babies Due to Stress in Pregnancy
- Mesupron Met Its Primary Objective of Demonstrating Efficacy in the Proof of Concept Phase II Breast Cancer Trial
- A Genetic Cause For Multiple Sclerosis Is Identified And Funded By Science Patron, Jeffrey Epstein
- Evaluation of a Single 1.000 mg Iron Dose as Ferric Carboxymaltose (FCM) for Fatigue Treatment in Iron Deficient Women - PREFER
- Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
June 18, 2012
- Spectrum Pharmaceuticals Announces Outstanding ZEVALIN Clinical Data In Aggressive Relapsed/Refratory Lymphoma; Presented at the 17th Congress of the European Hematology Association
- Infinity Stops Phase 2 Trials of Saridegib in Chondrosarcoma and Myelofibrosis
- Transition Therapeutics Announces Results of Phase 1 Clinical Study of TT-401
- Pharming Announces Presentation Of New Ruconest Clinical Data
- Aeterna Zentaris: Phase 2 Data for Perifosine as Monotherapy for Renal Cell Carcinoma Published in June Issue of Cancer
- Innate Announces Interim Results from Phase 2 Study of MIS416 in Secondary Progressive Multiple Sclerosis
- NPS Pharmaceuticals Reports Natpara Phase 3 Results to be Presented at ENDO, the annual meeting of The Endocrine Society
- RE-LY Sub-Analysis Suggests Pradaxa (dabigatran etexilate mesylate) Associated with Similar Bleeding Rates and Thromboembolic Complications in Surgery Versus Warfarin
- Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease
- PAREXEL Introduces The PAREXEL MyTrials Platform, A Fully-integrated eClinical Platform For More Efficient Clinical Trials
June 19, 2012
- Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
- Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
June 20, 2012
- Addex to Present Phase 2a Dipraglurant Data at Movement Disorder Society's International Congress
- Idenix Announces Positive Clinical Data for HCV Drug Candidates IDX184 and IDX719
- Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference
- Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ulcerative Colitis
June 21, 2012
- Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference
- Medigene Achieves Positive Formulation Study Results for Rhudex and Announces Phase II Proof-of-Concept Study for the Treatment of Autoimmune Diseases
- Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma
- Novel, Submicron Particle, Lower-Dose Diclofenac Demonstrated Relief of Acute Pain in Phase 3 Study
- Combined Northera (droxidopa) Data From Two Phase 3 Trials Confirm Symptom Improvement in Patients With Neurogenic OH
- Idera Pharmaceuticals Reports Preclinical Mechanism of Action Data on IMO-8400, a Novel TLR Inhibitor for Autoimmune Diseases
- ASCO Impact Report From Encuity Research Indicates Oncologists Are Likely to Shift Patient Treatment Plans
- Specialised Therapeutics Australia: New Drug to Fight Hospital Superbug Infection
- Novel, Submicron Particle, Lower-Dose Diclofenac Demonstrated Relief of Acute Pain in Phase 3 Study
- Sirona Biochem Announces Primate Results for SGLT Inhibitor for Type 2 Diabetes
- Adding Nevirapine to HIV Regimen Halves Newborn Transmission Rate
June 25, 2012
- Ventrus Biosciences Announces Results From Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease
- Curis Announces Publication of CUDC-907 Data in Clinical Cancer Research
- New Clinical Data Analyses Show Metreleptin Reduced Blood Glucose and Triglyceride Levels in Patients with Rare Forms of Lipodystrophy
- Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
- New Data From Phase Iii Study Showed That People With Her2-Positive Metastatic Breast Cancer Lived Longer With Genentech?s Perjeta
June 26, 2012
- Presidio Pharmaceuticals Successfully Completes Phase 1 Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients with Genotype-1 Infection
- OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
- Provectus Pharmaceuticals' Top-Line Final Phase 2 Data on PV-10 Presented at 2nd European Post-Chicago Melanoma Meeting 2012 on June 22, 2012
- Antares Pharma Announces Positive Results from VIBEX MTX Usability Study
- Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
- Data on Investigational Oral Octreolin for Acromegaly Demonstrate Growth Hormone Suppression
- Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
- Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide®
- Aeterna Zentaris: Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting
- Data From Phase II Trial of Prolor Biotech's Long-acting Human Growth Hormone Presented at Endo 2012
- Sunshine Biopharma's Adva-27a Found to Be Effective at Killing Multidrug Resistant Lung Cancer Cells
June 27, 2012
- Compugen Announces Validation Results for a Second Potential Immune Checkpoint Target for Cancer Immunotherapy
- Aeterna Zentaris: Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting
- Celtic Pharma: Data from New Drug Trial Offers Prospect for Enhanced Quality of Life for Children with Late Stage Brain Tumors
- PRIMA Study Shows Treatment with Privigen Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Infinity Reports Preclinical Data for IPI-145 and Announces Initial Indications for Phase 2 Development in Inflammation
- Data from New Drug Trial Offers Prospect for Enhanced Quality of Life for Children with Late Stage Brain Tumors
- Patients with atrial fibrillation who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa) compared to warfarin
- GlobeImmune's GI-4000 in Combination with Gemcitabine Following Surgery Shows Evidence of an Improvement in Survival in a Phase 2b Clinical Trial with Ras Mutation Positive Pancreas Cancer
- Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
June 28, 2012
- BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
- Final Data from Phase 2 Combination Study of VX-809 and KALYDECO (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
- GenSpera G-202 Data in Peer-Reviewed Journal Supports Prodrug Strategy
- Shire's Vpriv (velaglucerase alfa for injection) Shows Significant Improvement in Gaucher-Related Bone Disease
- Unigene's Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
- Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
June 29, 2012
- PROLOR Biotech To Present Data On Its Long-Acting Clotting Factors At Leading International Scientific Conference
- Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
- A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting
